TruthFan, Some additional information on relationships with AmplifyBio. Gemini of course.
Analysis of AmplifyBio's Collaborations and Partnerships (2021-Early 2025)
Executive Summary:
This report identifies companies that AmplifyBio, a preclinical Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) established in 2021, collaborated with, partnered with, or served as a client for between its inception and early 2025. The analysis of publicly available information, including news articles, press releases, and archived website content, reveals that AmplifyBio engaged in several strategic partnerships with entities such as Xcell Biosciences, Silo Group Pharma, RNAV8 Bio, Vector BioMed, Vitrian, and Stephen Burgess/AvaBurg LLC. Furthermore, AmplifyBio acquired select assets from PACT Pharma, enhancing its cell and gene therapy characterization capabilities. The company was also part of a significant research contract with the National Institutes of Health (NIH), alongside Battelle and Andelyn Biosciences. As a provider of comprehensive preclinical research and manufacturing services, AmplifyBio catered to a diverse clientele within the biotechnology and pharmaceutical sectors. Despite these collaborations and growth efforts, AmplifyBio announced the closure of its operations in early 2025.
Introduction:
AmplifyBio emerged in 2021 as a significant player in the preclinical drug development landscape, offering a suite of services as both a Contract Research Organization (CRO) and a Contract Development and Manufacturing Organization (CDMO). Operating for approximately four years, the company aimed to accelerate the development of next-generation therapies, including cell and gene therapies, mRNA-based therapeutics, and traditional biologics. This report focuses on the period from AmplifyBio's founding in 2021 to early 2025, aiming to delineate the network of companies it interacted with through collaborations, partnerships, or as a service provider. The information presented is derived from a thorough examination of publicly accessible sources, encompassing news articles, press releases issued by or about AmplifyBio, archived versions of the company's official website, and other relevant public announcements. The objective is to provide a comprehensive overview of AmplifyBio's external engagements within the biotech and pharmaceutical ecosystem during its operational lifespan.
Formal Partnerships and Collaborations:
AmplifyBio strategically engaged in several formal partnerships and collaborations to expand its service offerings, enhance its technological capabilities, and support the development of novel therapeutics.
3.1 Xcell Biosciences:
In May 2024, AmplifyBio entered into a partnership with Xcell Biosciences, a technology company specializing in cell and gene therapy manufacturing applications. This collaboration was specifically designed to optimize and improve the manufacturing process for engineered T-cell receptor (TCR) therapies aimed at treating solid tumors. Solid tumors present a considerable challenge in the field of cell therapy due to their immunosuppressive microenvironment, which hinders the effectiveness of T cells in targeting and eradicating cancer cells. This partnership signaled AmplifyBio's strategic emphasis on the advanced therapy domain, particularly in addressing the complexities of solid tumor treatment, a significant area of unmet medical need. The focus on "engineered T-cell receptor (TCR) therapies" also highlighted AmplifyBio's specialization within the broader immunotherapy landscape, as TCR-T cell therapies represent a cutting-edge approach in cancer research.
The collaboration leveraged Xcellbio's AVATAR Foundry platform, a cGMP cell therapy manufacturing system engineered to enhance the potency of cell and gene therapies. By utilizing this advanced technology, AmplifyBio aimed to improve its manufacturing capabilities, demonstrating a commitment to innovation and efficiency, as platforms like AVATAR Foundry can lead to more effective and scalable production processes crucial for the commercial viability of cell therapies. The joint efforts between AmplifyBio and Xcell Biosciences encompassed process development, preclinical analysis, and the planning for first-in-human clinical trials, indicating a comprehensive collaboration across the drug development spectrum. Further underscoring the significance of this partnership, AmplifyBio and Xcell Biosciences presented a joint poster at the International Society for Cell & Gene Therapy (ISCT) 2024 annual meeting. The poster detailed the metabolic conditioning of T cells within the AVATAR system to enhance their fitness and potency, showcasing the progress and visibility of this collaboration within the cell and gene therapy community. The partnership further expanded with Xcell Biosciences installing a new AVATAR Foundry system at AmplifyBio, enabling the advancement from small-scale research workflows to automated, clinical-scale manufacturing capabilities, signifying the success and long-term potential of this collaboration.
3.2 Silo Pharma:
Since 2022, Silo Pharma, a biopharmaceutical company focused on novel therapeutics for underserved conditions, partnered with AmplifyBio to advance the development of SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and anxiety. SPC-15 is identified as a novel serotonin 4 (5-HT4) receptor agonist. This collaboration demonstrated AmplifyBio's engagement in therapeutic areas beyond oncology, extending its preclinical CRO services to support the development of mental health treatments, thereby broadening its client base and market reach. AmplifyBio played a crucial role by conducting a non-Good Laboratory Practice (GLP) small animal dose-ranging study of SPC-15 and was subsequently contracted to perform a GLP toxicology study. These preclinical studies are essential steps in the process of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). The collaboration aimed to provide critical preclinical CRO services to support Silo Pharma's regulatory pathway, with the GLP toxicology study being a key requirement for demonstrating the safety of the drug candidate before it can be tested in human clinical trials. The duration of this partnership, spanning from 2022, suggested a robust and ongoing relationship, potentially indicative of mutual satisfaction and successful execution of previous projects.
3.3 RNAV8 Bio:
In April 2024, AmplifyBio announced a strategic partnership with RNAV8 Bio, a startup specializing in mRNA engineering platforms that utilize rational design alongside machine learning and artificial intelligence (ML/AI) techniques. This collaboration positioned AmplifyBio to offer comprehensive, end-to-end services within the rapidly evolving field of mRNA therapeutics, a market that has shown significant promise. The partnership aimed to establish a comprehensive "one-stop shop" for the entire spectrum of mRNA therapeutics development. RNAV8 Bio contributed its expertise in the design and optimization of mRNA sequences, while AmplifyBio provided its established preclinical CRO services, along with capabilities in process development, analytical development, and manufacturing. This integrated approach was intended to accelerate the progression of mRNA therapeutic candidates towards clinical trials. This partnership addressed the existing need for a more streamlined infrastructure in the mRNA therapeutic development landscape, as developers often encounter challenges in finding competent services and differentiating technologies. By integrating expertise from the initial design phase through to manufacturing, the collaboration aimed to enhance efficiency and reduce development timelines for their clients.
3.4 Vector BioMed:
AmplifyBio and Vector BioMed, a biomanufacturing company specializing in high-quality lentiviral vectors, announced a strategic partnership in October 2023. This collaboration strengthened AmplifyBio's presence in the gene therapy sector, addressing the critical need for reliable vector manufacturing, as lentiviral vectors are essential components in many gene therapy applications. As part of the agreement, AmplifyBio became the primary plasmid manufacturer for Vector BioMed's clientele. This arrangement allowed Vector BioMed's clients to access Good Manufacturing Practices (GMP) grade plasmid in customizable batch sizes, catering to various stages of development. The partnership aimed to create a comprehensive solution for the development of lentiviral vector-based therapies, providing Vector BioMed's clients with access to AmplifyBio's preclinical characterization and testing services. This collaboration formed a synergistic offering, effectively combining vector manufacturing with crucial preclinical development services, which could streamline the development process for companies focused on lentiviral-based gene therapies.
3.5 Vitrian:
In November 2024, Vitrian, a company focused on providing investment capital and capacity building services for biomanufacturing, made an initial investment of $50 million into AmplifyBio's Manufacturing Enablement Center (AMEC) located in New Albany, Ohio. This investment had the potential to increase to $65 million, marking the beginning of a broader commitment by Vitrian to support biomanufacturing in the Central Ohio region. This significant financial backing highlighted the potential and strategic importance of AmplifyBio's manufacturing facility within the biomanufacturing landscape. Vitrian's investment indicated a strong level of confidence in AmplifyBio's business model and its anticipated role in the industry. The investment was specifically directed towards supporting the buildout of AmplifyBio's 350,000 square foot GMP facility situated in New Albany, Ohio. The AMEC's location within Central Ohio's advanced manufacturing corridor, in proximity to facilities of Intel and Amgen, further underscored its strategic importance. This location in a growing biomanufacturing hub suggested potential for future collaborations and client acquisitions, as proximity to other major industry players can foster partnerships and create a supportive ecosystem. The partnership between Vitrian and AmplifyBio was structured as a buildout-leaseback arrangement.
3.6 Stephen Burgess/AvaBurg LLC:
AmplifyBio formalized a partnership with Stephen Burgess, through his consultancy AvaBurg LLC, in July 2024 to leverage his extensive expertise in lipid nanoparticle (LNP) formulations for the delivery of mRNA therapeutics. Dr. Burgess, a recognized leader in lipid chemistry and membrane dynamics with a distinguished career including his former role as Chief Scientific Officer at Avanti Polar Lipids, brought over three decades of experience in developing novel lipids. This partnership provided AmplifyBio with access to top-tier expertise in a component that is critical for the success of mRNA therapeutics. LNPs are essential for the effective and safe delivery of mRNA to target cells, and Dr. Burgess's specialized knowledge could significantly enhance AmplifyBio's service offerings in this increasingly important area of drug development. Dr. Burgess's role involved providing guidance on various aspects of LNP development, including custom lipid formulation, encapsulation techniques, optimization of payload delivery, and ensuring compliance with regulatory standards.
Client Engagements through CRO and CDMO Services:
Beyond these formal partnerships, AmplifyBio operated as a comprehensive preclinical CRO, offering a wide array of services encompassing toxicology, safety, and efficacy testing across various drug modalities. These services included both in vivo and in vitro studies, along with advanced bioanalytics, detailed characterization, and thorough safety assessments, such as biodistribution and immunological impact analysis. Additionally, AmplifyBio functioned as a CDMO, providing essential development, characterization, and manufacturing capabilities for advanced therapies, specifically in cell and gene therapies, mRNA, and plasmids. A key component of its CDMO capabilities was the AmplifyBio Manufacturing Enablement Center (AMEC), a facility that featured customizable B- and C-grade cleanroom suites. The availability of both B- and C-grade cleanrooms demonstrated AmplifyBio's capacity to handle a diverse range of manufacturing processes with varying levels of containment requirements, crucial for different stages of cell and gene therapy production to ensure both product quality and patient safety.
AmplifyBio proudly served "industry leaders" within the biotech and pharmaceutical sectors and experienced significant growth in its client base, adding 23 new clients in its first year of operation and an additional 28 new clients in the subsequent year. Its clientele included companies focused on developing both traditional small molecule drugs and innovative advanced therapies. These biotech and pharmaceutical companies sought AmplifyBio's expertise for preclinical research and manufacturing services to support their therapeutic candidates. This substantial growth in client numbers during its initial years highlighted AmplifyBio's success in attracting business and establishing a strong presence in the market, suggesting a high demand for its specialized services and an effective market entry strategy. AmplifyBio's reported revenue range of $10 million to $50 million indicated a significant volume of client engagements and projects undertaken during its operational period. However, the company's closure announcement in early 2025 pointed to a reliance on early-stage biotech companies for a significant portion of its revenue, a sector that experienced a notable scarcity of investor financing in the preceding years, ultimately impacting AmplifyBio's ability to sustain its growth. This suggested a potential vulnerability in its business model, as its financial health was closely linked to the often-volatile investment landscape for early-stage companies.
PACT Pharma Asset Acquisition:
In a strategic move to bolster its capabilities in the rapidly evolving field of cell and gene therapy, AmplifyBio acquired select assets from PACT Pharma in October 2022. This acquisition included advanced characterization platforms, sophisticated bioinformatics capabilities, and a team of 40 experienced drug development experts from PACT Pharma. Furthermore, AmplifyBio also took over PACT Pharma's advanced laboratory facility located in South San Francisco. The primary objective of this acquisition was to significantly enhance AmplifyBio's service offerings in the cell and gene therapy domain, with a particular emphasis on strengthening its characterization capabilities. This enhancement allowed AmplifyBio to differentiate cell and gene therapies based on their safety and efficacy profiles, a critical factor in the development of these complex medicines. This acquisition represented a deliberate effort by AmplifyBio to strengthen its position within the competitive cell and gene therapy market by integrating advanced analytical and characterization technologies and expertise, recognizing that robust characterization is essential for ensuring the safety and efficacy of these advanced therapeutic modalities.
National Institutes of Health (NIH) Collaboration:
In January 2023, a collaborative team comprising Battelle, AmplifyBio, and Andelyn Biosciences secured a position on an eight-year, $149 million indefinite delivery, indefinite quantity (IDIQ) contract vehicle from the National Institute of Neurological Disorders and Stroke (NINDS). As part of this significant contract, the team was tasked with providing crucial manufacturing and nonclinical support for the translational development of innovative therapeutic biotechnology products aimed at addressing a wide range of neurological conditions. AmplifyBio's specific role within this collaboration involved leveraging its expertise in preclinical study capabilities and advanced therapy analytics. Notably, AmplifyBio was responsible for performing IND-enabling GLP preclinical studies, which are critical for advancing therapeutic candidates towards human clinical trials. Further demonstrating the team's capabilities, in November 2023, they were awarded a specific task order under this contract, focused on the manufacturing of plasmid and adeno-associated virus (AAV) vectors, along with conducting IND-enabling studies for Aspartylglucosaminuria (AGU), a severe and progressive genetic neurological disorder. Under this task order, Andelyn Biosciences was responsible for the manufacturing of the necessary gene therapy components, while Battelle provided essential assay support for the ELISA and enzyme activity portions of the studies. AmplifyBio's involvement in this significant NIH contract underscored its credibility and recognized expertise in supporting substantial research initiatives within the critical field of neurological disorders. Securing a position on such a large NIH contract vehicle signifies a rigorous evaluation process and a strong affirmation of the team's collective capabilities in advancing novel therapies.
Investor Relationships as Collaborations:
AmplifyBio received significant financial backing from a diverse group of investors, including Battelle, Viking Global Investors, Casdin Capital, Narya Capital , and Hercules Capital. These investors played a crucial role in providing the necessary capital to support AmplifyBio's operational activities and strategic expansion plans. Notably, Battelle, from which AmplifyBio was spun out in May 2021, maintained a close relationship with the new entity, holding two seats on AmplifyBio's five-person board of directors. The spin-out from Battelle provided AmplifyBio with a robust foundation and access to Battelle's extensive experience and expertise in research and development, likely contributing to AmplifyBio's initial credibility and resource base. Hercules Capital further supported AmplifyBio's growth by providing $50 million in debt financing, aimed at accelerating the company's overall business plan. Additionally, Vitrian, beyond its role as a strategic partner, also acted as an investor in AmplifyBio's AMEC facility, engaging in a buildout-leaseback partnership that facilitated the development of the manufacturing capabilities. The diverse range of investors, encompassing venture capital firms, debt financing institutions, and strategic investment partners, reflected a comprehensive and multi-faceted approach to securing the financial resources required to support AmplifyBio's growth trajectory and strategic objectives.
Conclusion:
AmplifyBio, during its operational period from 2021 to early 2025, established a network of strategic collaborations and served a broad range of clients within the biotechnology and pharmaceutical industries. Key partnerships were formed with Xcell Biosciences to enhance cell therapy manufacturing, Silo Pharma to advance novel therapeutics for PTSD, RNAV8 Bio to offer comprehensive mRNA development services, Vector BioMed to strengthen capabilities in gene therapy vector manufacturing, Vitrian for a significant investment in its manufacturing facility, and Stephen Burgess for specialized expertise in lipid nanoparticle formulations. Furthermore, AmplifyBio strategically acquired assets from PACT Pharma to enhance its cell and gene therapy characterization capabilities and was a part of a significant NIH contract alongside Battelle and Andelyn Biosciences. As a CRO and CDMO, AmplifyBio supported numerous biotech and pharmaceutical companies in the development of various advanced therapies, from preclinical research to manufacturing. Despite these collaborations and growth efforts, AmplifyBio announced its closure in early 2025, likely due to challenging market conditions and a scarcity of investor financing for early-stage biotech companies, which significantly impacted its growth strategy.
Appendix: Summary of AmplifyBio's Key Partnerships (2021-Early 2025)
| Partner Company/Entity Name | Nature of Collaboration/Partnership | Timeframe (if specified) | Relevant Snippet IDs |
|---|---|---|---|
| Xcell Biosciences | Partnership to manufacture solid tumor-targeting TCR-T cell therapy, utilizing Xcellbio's AVATAR Foundry platform for process development, preclinical analysis, and first-in-human trials. | May 2024 - Early 2025 | |
| Silo Pharma | Preclinical CRO partner for advancing SPC-15, an intranasal prophylactic treatment for PTSD and anxiety, including dose-ranging and GLP toxicology studies. | 2022 - Early 2025 | |
| RNAV8 Bio | Strategic partnership to support mRNA therapeutic developers from sequence design to GMP manufacture, combining RNAV8's design expertise with AmplifyBio's CRO and CDMO services. | April 2024 - Early 2025 | |
| Vector BioMed | Strategic partnership for AmplifyBio to become the primary plasmid manufacturer for Vector BioMed's clients, offering a one-stop solution for lentiviral vector-based therapy development. | October 2023 - Early 2025 | |
| Vitrian | Investment of up to $65 million in AmplifyBio's AMEC facility and broader partnership for biomanufacturing capacity in Central Ohio. | November 2024 - Early 2025 | |
| Stephen Burgess/AvaBurg LLC | Partnership for expertise in lipid nanoparticle (LNP) formulations to enhance mRNA delivery capabilities, providing guidance on formulation, encapsulation, and regulatory compliance. | July 2024 - Early 2025 | |
| PACT Pharma | Acquisition of select assets, including characterization platforms, bioinformatics capabilities, and personnel, to enhance AmplifyBio's cell and gene therapy service offerings. | October 2022 | |
| Battelle & Andelyn Biosciences | Part of a team awarded an NIH contract to provide manufacturing and nonclinical support for translational development of therapeutic biotechnology products for neurological conditions. | January 2023 - Early 2025 | |
Market Data 
Markets 
AI
